About Shantani Proteome Analytics
Shantani Proteome Analytics is a Healthcare company based in Pune (India) founded in 2010. It operates as a drug discovery services are delivered via chemical-proteomics technologies. Shantani Proteome Analytics has raised $987.61 thousand across 4 funding rounds from investors including Entrepreneurship Development Institute of India, India Innovation Fund and Blume Ventures. The company has 1 employees. Shantani Proteome Analytics was last valued at $2.38 million in June 2013. Its Indian entity Shantani Proteome Analytics Private Limited reported revenue of ₹11.19 Cr. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Chemical Proteomics. Its competitors include Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi and 5 more; 10 of its 10 listed competitors have raised funding.
Company details
Founded in 2010 and based in Pune, India, Shantani Proteome Analytics operates in the biotechnology sector, focusing on drug discovery and development. Proprietary chemical proteomics platforms, including SCLS and UPT workflows, are utilized to analyze targets and mechanisms of bioactive molecules. These integrate chemical biology, biophysics, and cell molecular biology approaches to support research operations.
- Headquarters Pune, India
- Employees 1
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website shantani.com
- Social LinkedIn X
- Legal Name Shantani Proteome Analytics Private Limited
- Date of Incorporation 12 May, 2010
- Jurisdiction Pune, Maharashtra, India
- Annual Revenue₹11.19 Cr
FY 2025 · 0% YoY
- Net Profit₹4.58 Cr
FY 2025 · 41% margin
- EBITDA₹6.72 Cr
FY 2025 · 60% margin
- Total Equity Funding$987.61K (USD)
in 4 rounds
- Latest Funding Round$181.61K (USD), Seed
Jan 2015
- Investors
- Employee Count1
Associated legal entities of Shantani Proteome Analytics
Shantani Proteome Analytics operates through Shantani Proteome Analytics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Shantani Proteome Analytics Private Limited CIN U74900PN2010PTC136292 | Active | 12 May 2010 | Pune, Maharashtra | ₹11.2 Cr | – | 2 | View details |
Funding Insights of Shantani Proteome Analytics
Shantani Proteome Analytics has successfully raised a total of $987.61K across 4 strategic funding rounds. The most recent funding activity was a Seed round of $181.61 thousand completed in January 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $987,612
- Total Rounds 4
- Last Round Seed — $181,608
- First Round $44,447
(May 2011)
- Investors Count 6
All 4 funding rounds of Shantani Proteome Analytics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2015 | $181,608 | Seed | – | India Innovation Fund | |
| Jun 2013 | $579,352 | Seed | $2.38M | India Innovation Fund | |
| Jun 2012 | $182,205 | Seed | $694,290 | India Innovation Fund | |
| May 2011 | $44,447 | Seed | $••••• | Entrepreneurship Development Institute of India | – |
| Date | Valuation | Stage |
|---|---|---|
| Jun 2013 | $2.38M | •••••••• |
Last known valuation $2.38M (Jun 2013). 6 investors in total: 3 institutional and 3 angel.
Investors in Shantani Proteome Analytics
Shantani Proteome Analytics has secured backing from 6 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Entrepreneurship Development Institute of India, India Innovation Fund and Blume Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
India focused early stage mivro VC firm | 2010 | indiainnovationfund.in | Bengaluru, India | |
Seed and early-stage investments are made across sectors in India. | – | blume.vc | Mumbai, India | |
Entrepreneurship education, research, and training are provided to diverse groups. | 1983 | ediindia.org | Gandhinagar, India | |
VP Vara Prasad Reddy | - | – | unknown_2ca90a17043f4767b | - |
SR Sravanthi Reddy | - | – | unknown_665db0a9f73b447fa | - |
SM Sanjay Mirchandani | - | – | unknown_e5452bef75fd40c69 | - |
Investor details for Shantani Proteome Analytics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Shantani Proteome Analytics Private Limited (Shantani Proteome Analytics)
Shantani Proteome Analytics Private Limited is the primary company behind Shantani Proteome Analytics. The board of Shantani Proteome Analytics Private Limited currently have 2 directors; the longest-serving is Vikas Saxena, appointed in 2010. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vikas Saxena DIN 02679589 | Director | 12 May 2010 | 16 yrs 5 mo | Shantani Proteome Analytics Private Limited |
| Chaitanya Saxena DIN 03021600 | Whole-time director | 12 May 2010 | 16 yrs 5 mo | Shantani Proteome Analytics Private Limited |
People of Shantani Proteome Analytics
1 people are tracked at Shantani Proteome Analytics (1 in leadership); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
| Director | Leadership |
Complete people profiles for Shantani Proteome Analytics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Shantani Proteome Analytics
Figures of Shantani Proteome Analytics Private Limited, the primary company behind Shantani Proteome Analytics, for FY 2025. Revenue was ₹11.19 Cr (0% year on year). Net profit was ₹4.58 Cr (41% margin). EBITDA was ₹6.72 Cr (60% margin). Revenue has grown at a compounded annual rate of +8% over three years and +39% over five years.
- ₹11.19 CrRevenue · FY 2025 · 0% YoY
- ₹4.58 CrNet profit · 41% margin
- ₹6.72 CrEBITDA · 60% margin
- ₹9.3 LakhPaid-up capital
- +8%Revenue CAGR, 3 years
- +39%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Shantani Proteome Analytics Private Limited are on its company page.
Detailed financial statements for Shantani Proteome Analytics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Shantani Proteome Analytics
4 dated milestones of Shantani Proteome Analytics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Shantani Proteome Analytics is founded.
- Funding First funding round of $44K.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Seed, of $182K.
Competitors of Shantani Proteome Analytics
Shantani Proteome Analytics has 10 listed competitors in our database, 10 of them funded. They include Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| amunix.com | 2006 | Mountain View, United States | $200.59M | 82 | Peptide-based therapeutics are developed for cancers and immune disorders. | |
| biognosys.com | 2008 | Schlieren, Switzerland | $9.13M | – | Proteomics services are delivered via discovery and targeted platforms. | |
| elektrofi.com | 2016 | Boston, United States | $152.25M | 71 | Digital platform transforming the delivery of biologic medicines | |
| proteinsimple.com | 2004 | San Jose, United States | $114.29M | 157 | Provider tools to help researchers with protein analysis | |
| arzeda.com | 2008 | Seattle, United States | $94.96M | 66 | Synthetic enzymes are designed using computational technology for industrial applications. | |
| aalphabio.com | 2017 | Seattle, United States | $45.24M | 48 | Developer of cell-based tool for the measurements of protein interactions | |
| glyphic.bio | 2021 | San Francisco, United States | $39.2M | 26 | Next-generation protein sequencing platform is developed for proteome analysis. | |
| dynamic-biosensors.com | 2011 | Planegg, Germany | $5.83M | 51 | Label-free solutions for molecular interactions and biophysical analysis are provided. |
Detailed competitors of Shantani Proteome Analytics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Shantani Proteome Analytics (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Shantani Proteome Analytics
Complete news archive for Shantani Proteome Analytics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shantani Proteome Analytics
Shantani Proteome Analytics was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Shantani Proteome Analytics is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
Shantani Proteome Analytics is a funded company, having raised a total of $987.61K across 4 funding rounds to date. The company's 1st funding round was a Seed of $44.45K, raised on May 2011.
Shantani Proteome Analytics has 1 employees.
The primary company behind Shantani Proteome Analytics, Shantani Proteome Analytics Private Limited, reported revenue of ₹11.19 Cr for FY 2025, down 0% year on year.
Founded in 2010 and based in Pune, India, Shantani Proteome Analytics operates in the biotechnology sector, focusing on drug discovery and development. Proprietary chemical proteomics platforms, including SCLS and UPT workflows, are utilized to analyze targets and mechanisms of bioactive molecules. These integrate chemical biology, biophysics, and cell molecular biology approaches to support research operations.
Shantani Proteome Analytics's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.
Shantani Proteome Analytics has 6 investors. Key investors include Entrepreneurship Development Institute of India, India Innovation Fund, Blume Ventures, Vara Prasad Reddy, and Sravanthi Reddy.
The valuation of Shantani Proteome Analytics is $2.38M as of Jun 2013.
Shantani Proteome Analytics operates through Shantani Proteome Analytics Private Limited.
The legal entities of Shantani Proteome Analytics currently have 2 directors, including Vikas Saxena, Chaitanya Saxena.